All polymorphisms studied in this paper [PMID: 18385279] , total : 1 polymorphisms

Title : The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis.

Abstract : OBJECTIVE: To assess the effect of a functional polymorphism (676T>G, M196R) in the tumour necrosis factor receptor super family 1b (TNFSF1b) gene on disease activity, radiological joint damage and response to infliximab and adalimumab treatment in patients with rheumatoid arthritis (RA). METHODS: Two cohorts of patients with RA were genotyped for the 676T>G polymorphism (rs1061622) in exon 6 of the TNFSF1b gene by restriction fragment length polymorphism analysis. One cohort (n = 234) included patients from the Dutch Rheumatoid Arthritis Monitoring register with detailed information on their response to anti-TNF therapy (infliximab and adalimumab), the other cohort comprised patients from a long-term observational early inception cohort at our centre (n = 248). RESULTS: The 676T>G polymorphism was not associated with anti-TNF response after 3 or 6 months of treatment. Linear regression analysis showed no significant difference in the progression of radiological joint damage during the first 3 and 6 years of disease between the three genotype groups (TT, TG and GG). Additionally, no difference in mean disease activity between genotypes was seen after 3 and 6 years of disease. CONCLUSION: Despite its demonstrated functionality, the 676T>G polymorphism in the TNFSF1b gene does not have a major role in either the response to anti-TNF therapy or in the disease severity or radiological progression in RA.

Author : Toonen EJ,Coenen MJ,Kievit W,Fransen J,Eijsbouts AM,Scheffer H,Radstake TR,Creemers MC,de Rooij DJ,van Riel PL,Franke B,Barrera P,

Source : Ann Rheum Dis. 2008 Aug;67(8):1174-7. doi: 10.1136/ard.2008.088138. Epub 2008 Apr 2.

No.	Polymorphism name	Gene Symbol	Entrez Gene ID
1	rs1061622	TNFRSF1B	7133